America’s Food and Drug Administration (FDA) has approved a longer length of therapy for a medication treating adult kidney transplant patients at high risk of cytomegalovirus disease, it has been reported.
Valcyte has been developed by Genentech – a member of the Roche Group.
Cytomegalovirus is a common virus that infects most people at some time, rarely causing problems.
But it can cause serious infections for patients who have received organ transplants or in immunodeficient patients – for example those with HIV or AIDS.
Genentech said that longer, preventive treatment with Valcyte reduced the incidence of the disease in high-risk patients from 36.8% to 16.8% a year after they received a transplanted kidney.
Copyright Press Association 2010